Open Beta
TREN
MetriLume
TREN

US marketsAQST

SEC-sourced researchBeta

AQST

Aquestive Therapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001398733
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Oct 7, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 57,561,000.0000 USD; December 2025: 44,545,000.0000 USD57.6M USD0 USD0December 2024December 2025
AQST · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202457,561,000.0000Mar 4, 2026
December 202544,545,000.0000Mar 4, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202544,545,000.0000-83,784,000.0000-52,432,000.0000160,425,000.0000194,087,000.0000Mar 4, 2026
December 202457,561,000.0000-44,137,000.0000-35,759,000.0000101,424,000.0000161,580,000.0000Mar 4, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

25/100
Profitability0
Growth27
Balance sheet0
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$44.55MJan 1, 2025 – Dec 31, 2025Mar 4, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$57.56MJan 1, 2024 – Dec 31, 2024Mar 4, 202610-K
Net incomeNetIncomeLoss-$83.78MJan 1, 2025 – Dec 31, 2025Mar 4, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$52.43MJan 1, 2025 – Dec 31, 2025Mar 4, 202610-K
Total assetsAssets$160.43MDec 31, 2025Mar 4, 202610-K
Total liabilitiesLiabilities$194.09MDec 31, 2025Mar 4, 202610-K

New filings

Explore methodology ↗